Table 1:
Clinical and imaging outcomes
| GPIIb/IIIa Inhibitors (n = 54) | Cangrelor (n = 15) | Total (n = 69) | P Value | |
|---|---|---|---|---|
| Arterial occlusion lesion score 2–3 | 44/54 (81.5%) | 15/15 (100.0%) | 59/69 (85.5%) | .071 |
| Final mTICI 2b-3 | 39/54 (75.0%) | 14/15 (93.3%) | 53/69 (79.1%) | .124 |
| Final mTICI 2c-3 | 16/52 (30.8%) | 12/15 (80.0%) | 28/67 (41.8%) | <.001 |
| Final mTICI 3 | 11/52 (21.2%) | 7/15 (46.7%) | 18/67 (26.9%) | .050 |
| Puncture-to-recanalization delay (median) (IQR) | 80 (55−133) | 107 (82–149) | 87 (58–135) | .573 |
| Perioperative complication | 11/54 (20.4%) | 1/15 (6.7%) | 12/69 (17.4%) | .215 |
| Day 1 NIHSS (median) (IQR)a | 12 (7–16) | 11 (5–16) | 12 (6–16) | .462 |
| Day 1 ASPECTS (median) (IQR) | 6 (4–7) | 7 (6–8) | 6 (4–7) | .089 |
| Intracranial artery patency on day 1 imaging follow-up | 42/54 (79.2%) | 13/15 (86.7%) | 55/69 (80.9%) | .519 |
| Any ICH | 20/54 (37.0%) | 4/15 (26.7%) | 24/69 (34.8%) | .456 |
| sICH | 0/53 (0.0%) | 1/15 (6.7%) | 1 /68 (1.5%) | .058 |
| ECASS hemorrhage subtypes | .798 | |||
| HI-1 | 8/53 (15.1%) | 2/15 (13.3%) | 10/68 (14.7%) | |
| HI-2 | 7/53 (13.2%) | 1/15 (6.7%) | 8/68 (11.8%) | |
| PH-1 | 1/53 (1.9%) | 1/15 (6.7%) | 2/68 (2.9%) | |
| PH-2 | 0/53 (0%) | 0/15 (0%) | 0/69 (0%) | |
| Remote ICH | 1/53 (1.9%) | 0/15 (0.0%) | 1/68 (1.5%) | |
| Subarachnoid hemorrhage | 2/53 (3.8%) | 0/15 (0.0%) | 2/68 (2.9%) | |
| 90-Day mRS 0–2 | 17/54 (31.5%) | 6/15 (40.0%) | 23/69 (33.3%) | .536 |
| 90-Day mortality | 16/54 (29.6%) | 3/15 (20.0%) | 19/69 (27.5%) | .460 |
Note:—IQR indicates interquartile range; HI-1, hemorrhagic infarction type 1; HI-2, hemorrhagic infarction type 2; PH-1, parenchymal hematoma type 1; PH-2, parenchymal hematoma type 2.
a
Missing values in 26 patients.